全文获取类型
收费全文 | 149630篇 |
免费 | 11514篇 |
国内免费 | 4178篇 |
专业分类
耳鼻咽喉 | 1583篇 |
儿科学 | 2562篇 |
妇产科学 | 2368篇 |
基础医学 | 10899篇 |
口腔科学 | 3155篇 |
临床医学 | 17838篇 |
内科学 | 20018篇 |
皮肤病学 | 2450篇 |
神经病学 | 15272篇 |
特种医学 | 4589篇 |
外国民族医学 | 39篇 |
外科学 | 15741篇 |
综合类 | 20393篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5633篇 |
眼科学 | 2346篇 |
药学 | 11348篇 |
79篇 | |
中国医学 | 11619篇 |
肿瘤学 | 17365篇 |
出版年
2024年 | 236篇 |
2023年 | 2590篇 |
2022年 | 3896篇 |
2021年 | 6595篇 |
2020年 | 6203篇 |
2019年 | 5498篇 |
2018年 | 5232篇 |
2017年 | 5718篇 |
2016年 | 5894篇 |
2015年 | 5705篇 |
2014年 | 10358篇 |
2013年 | 12860篇 |
2012年 | 8450篇 |
2011年 | 9195篇 |
2010年 | 7593篇 |
2009年 | 7013篇 |
2008年 | 6940篇 |
2007年 | 7342篇 |
2006年 | 6595篇 |
2005年 | 5825篇 |
2004年 | 4799篇 |
2003年 | 4384篇 |
2002年 | 3613篇 |
2001年 | 3171篇 |
2000年 | 2661篇 |
1999年 | 2172篇 |
1998年 | 1793篇 |
1997年 | 1538篇 |
1996年 | 1308篇 |
1995年 | 1179篇 |
1994年 | 1012篇 |
1993年 | 750篇 |
1992年 | 755篇 |
1991年 | 663篇 |
1990年 | 603篇 |
1989年 | 544篇 |
1988年 | 492篇 |
1987年 | 459篇 |
1986年 | 368篇 |
1985年 | 492篇 |
1984年 | 437篇 |
1983年 | 322篇 |
1982年 | 333篇 |
1981年 | 320篇 |
1980年 | 283篇 |
1979年 | 260篇 |
1978年 | 175篇 |
1977年 | 136篇 |
1976年 | 140篇 |
1975年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
Repetitive transcranial magnetic stimulation, as a relatively new type of rehabilitation treatment, is a painless and non-invasive method for altering brain excitability. Repetitive transcranial magnetic stimulation has been widely used in the neurorehabilitation of stroke patients. Here, we used CiteSpace software to visually analyze 315 studies concerning repetitive transcranial magnetic stimulation for stroke rehabilitation from 1999 to 2019, indexed by Web of Science, to clarify the research hotspots in different periods and characterize the gradual process of discovery in this field. We found that four main points were generally accepted:(1) repetitive transcranial magnetic stimulation has a positive effect on motor function recovery in patients with subcortical stroke;(2) it may be more advantageous for stroke patients to receive low-frequency repetitive transcranial magnetic stimulation in the unaffected hemispheres than to receive high-frequency repetitive transcranial magnetic stimulation in affected hemisphere;(3) low-frequency repetitive transcranial magnetic stimulation has become a potential therapeutic tool for patients with non-fluent aphasia after chronic stroke for neurological rehabilitation and language recovery; and(4) there are some limitations to these classic clinical studies, such as small sample size and low test efficiency. Our assessment indicates that prospective, multi-center, large-sample, randomized controlled clinical trials are still needed to further verify the effectiveness of various repetitive transcranial magnetic stimulation programs for the rehabilitation of stroke patients. 相似文献
35.
观察并评估角膜电刺激对糖尿病大鼠前部缺血性视神经病变(AION)模型的影响。方法:实验 研究。健康雄性Sparague-Dawley大鼠40只,随机分组后抽出8只作为正常大鼠组。余下32只先予 以链脲佐菌素腹腔注射建立糖尿病大鼠模型,将造模成功的大鼠随机抽出8只作为糖尿病组,余下 24只糖尿病大鼠采用孟加拉玫瑰红联合532 nm激光方法建立AION大鼠模型。将24只造模成功的 AION大鼠随机分成3组,每组8只,分别为AION模型组,不予任何处理;电刺激组,予以角膜电刺 激(刺激参数为:电流1 mA,频率20 Hz,波宽1 ms/phase,刺激时间1 h,隔日1次,刺激2周);假电 刺激组,电极安放位置与电刺激组相同,仅不接通电源。2周后5组大鼠进行眼底照相、光学相干断 层扫描和视觉诱发电位,然后处死,行视网膜及视神经冰冻切片,苏木精伊红染色观察。数据采用 单因素方差分析和LSD-t检验进行分析。结果:正常大鼠组视盘上半部视网膜厚度为(211±13)μm, 糖尿病大鼠组为(206±16)μm,AION模型组为(240±54)μm,假电刺激组为(216±11)μm,电刺 激组为(198±4)μm,5组视盘上半部视网膜厚度差异有统计学意义(F=2.854,P=0.038)。其中AION 模型组视盘上半部视网膜厚度高于正常组、糖尿病组、电刺激组,差异均有统计学意义(P<0.05); 正常组与糖尿病组差异无统计学意义,AION模型组与假电刺激组未见明显差异。视觉诱发电位示 AION模型组N1潜伏期较电刺激组延长,差异有统计学意义(t=4.1,P<0.001);AION模型组P1潜伏 期较正常组、糖尿病组、假电刺激组、电刺激组延长,差异均有统计学意义(t=4.1、2.5、2.6、3.2, P<0.05);电刺激组N1-P1波幅大于假电刺激组,差异有统计学意义(t=4.0,P<0.001)。结论:角膜电 刺激能促进糖尿病大鼠前部缺血性视神经病变模型肿胀的视盘变薄,加速视盘水肿的消退,同时在 一定程度上改善视功能。 相似文献
36.
声带运动障碍的病因和临床表现复杂多变,涉及多学科,从病因上分为神经源性和非神经源性。对于神经源性声带运动障碍的诊治,首先通过喉镜等检查明确有无声带运动障碍及严重程度,值得注意的是声带纵向张力变化障碍也属于运动障碍的范畴;然后采用喉肌电图(LEMG)检查进行定性分析,在确诊神经源性损伤后,进一步对神经损伤部位进行定位诊断并查找导致神经损伤的病因;同时根据喉部神经电生理评估结果,判断预后。最后综合上述的评估结果制定相应的治疗策略。 相似文献
37.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
38.
39.
40.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献